Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.286
Sell
RSI(14)
47.473
Neutral
STOCH(KDJ)(9,3,3)
35.742
Buy
ATR(14)
0.705
Low Volatility
CCI(14)
-37.789
Neutral
Williams %R
60.084
Sell
TRIX(12,20)
-0.199
Sell
StochRSI(14)
100.000
Overbought
Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
12.040USD
+0.150+1.26%
Close 07-29 16:00（ET）Quotes delayed by 15 min
316.06MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.26%
5 Days
+5.24%
1 Month
-5.20%
6 Months
-4.52%
Year to Date
-10.62%
1 Year
+8.96%
Key Figures
12.010Open
12.235High
52.83KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.20%Turnover Ratio
11.890Prev. Close
11.561Low
488.77KTurnover
LossP/E Static
3.38P/B
0.00%Div Yield TTM
-28.43%ROA
17.15052wk High
0.53Volume Ratio
-37.92MNet Profit
26.25MShares
-0.9227EPS TTM
0.28Beta
-29.58%ROE
9.85052wk Low
5.67%Amplitude
100.00%Gross Margin
316.06MMarket Cap
-3.23Reward/Risk
3.45%Risk Rate
TradingKey Stock Score of Benitec Biopharma Inc
Currency: USD Updated: 2026-07-29Key Insights
Benitec Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.17.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Benitec Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Benitec Biopharma Inc Highlights
StrengthsRisks
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -13.06, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.05M shares, increasing 13.43% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.36K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
24.167
Target Price
+108.69%
Upside Space
Benitec Biopharma Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
7
analysts
Buy
Current Rating
24.167
Target Price
+108.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Benitec Biopharma Inc
BNTC
7
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
11.686
Buy
MA10
11.917
Buy
MA20
12.554
Sell
MA50
11.928
Buy
MA100
11.912
Buy
MA200
12.402
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Benitec Biopharma Inc Info
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Ticker SymbolBNTC
CompanyBenitec Biopharma Inc
CEOBanks (Jerel A)
Websitehttps://benitec.com/
Shareholders
Related Instruments
-0.75%
-0.41%
+0.49%
+0.16%
-1.07%
-0.64%
-1.34%
+1.26%
-1.15%
-0.30%
-0.72%
-1.36%
-0.03%
-0.94%
-1.44%
0.00%
+0.24%
+1.34%
+1.29%
-1.45%Popular Instruments
51689.200
+131.200 (+0.25%)
27388.000
+274.200 (+1.01%)
7346.700
+43.900 (+0.60%)
14501.000
-185.000 (-1.26%)
62066.000
+1137.000 (+1.87%)
6250.100
+29.600 (+0.48%)
83.010
-0.931 (-1.11%)
338.360
-1.720 (-0.51%)
190.240
-6.770 (-3.44%)
4053.590
-13.550 (-0.33%)
FAQs
What is the current price of Benitec Biopharma Inc (BNTC)?
The current price of Benitec Biopharma Inc (BNTC) is 12.04.
What is the symbol of Benitec Biopharma Inc?
The ticker symbol of Benitec Biopharma Inc is BNTC.
What is the 52-week high of Benitec Biopharma Inc?
The 52-week high of Benitec Biopharma Inc is 17.15.
What is the 52-week low of Benitec Biopharma Inc?
The 52-week low of Benitec Biopharma Inc is 9.85.
What is the market capitalization of Benitec Biopharma Inc?
The market capitalization of Benitec Biopharma Inc is 316.06M.
Is Benitec Biopharma Inc (BNTC) currently rated as Buy, Hold, or Sell?
According to analysts, Benitec Biopharma Inc (BNTC) has an overall rating of Buy, with a price target of 24.17.
What is the Earnings Per Share (EPS TTM) of Benitec Biopharma Inc (BNTC)?
The Earnings Per Share (EPS TTM) of Benitec Biopharma Inc (BNTC) is -1.05.